Parkinson's disease dementia (PDD) is the diagnosis when cognitive impairment emerges in a patient with established Parkinson's disease — meeting the temporal criterion of dementia developing more than 1 year after motor symptoms began. The pathology — alpha-synuclein spread from brainstem to cortex — is shared with Lewy body dementia; the distinction is timing.
The 1-year rule distinguishes PDD from LBD. Dementia developing >1 year after motor symptoms = PDD. Dementia developing before or within 1 year of motor symptoms = LBD. Same underlying synucleinopathy, different clinical presentation by timing. The distinction guides research and prognosis discussions; clinical management overlaps substantially.
Cognitive profile of PDD: executive dysfunction prominent (planning, working memory, attention), visuospatial impairment (often striking — patient cannot copy a clock face or interlocking pentagons), processing speed slowing, fluctuating attention. Memory impairment is typically of retrieval more than encoding — cued recall often improves performance, unlike in classic Alzheimer's amnestic pattern.
Visual hallucinations are common in PDD — typically well-formed, often involving people or animals, sometimes with insight. Distinct from frank psychotic illness in many patients; can be tolerated when not distressing.
REM sleep behavior disorder is frequent in PDD — often present years before motor symptoms began. Patients who had RBD before PD diagnosis are at higher risk of developing PDD.
Other psychiatric symptoms: depression (40-50% of PDD patients), anxiety, apathy (often confused with depression), impulse control disorders (related to dopamine agonist therapy — pathological gambling, hypersexuality, compulsive shopping, hyperphagia). Address dopamine agonist side effects before attributing to disease progression.
Treatment of cognitive symptoms: Rivastigmine has FDA approval specifically for PDD and best evidence. Modest benefit; can be transformative in selected patients. Other cholinesterase inhibitors used off-label.
Management of psychotic symptoms: Pimavanserin is FDA-approved for Parkinson's disease psychosis — no dopamine receptor effects, doesn't worsen parkinsonism. Quetiapine at low doses (12.5-50 mg) as alternative. Avoid haloperidol, risperidone, olanzapine — significant neuroleptic sensitivity in synucleinopathy.
Motor symptom optimization: coordinate with neurology — sometimes reducing dopaminergic medication helps psychotic symptoms at the cost of motor function. Risk-benefit individualized. Deep brain stimulation considered in selected patients prior to severe cognitive decline.
The trajectory: PDD typically progresses over years. Eventually, most patients require substantial caregiver support. Family education about expected progression, advance care planning, and caregiver support are central to good care.
When you encounter a Parkinson's patient with new cognitive decline, structured assessment is appropriate. The 1-year rule guides nomenclature. Rivastigmine and cautious management of comorbid psychiatric symptoms are the mainstays.